[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @JoseRestonVA Jose Hurtado Jose Hurtado posts on X about acquisition, $abvx, bloomberg, ticker the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::4861119254/interactions)  - X Week XXXXXX +152% - X Month XXXXXX -XX% - X Months XXXXXXX +22% - X Year XXXXXXX +202% ### Mentions: XX [#](/creator/twitter::4861119254/posts_active)  - X Month XX -XX% - X Months XXX +39% - X Year XXX +168% ### Followers: XXXXX [#](/creator/twitter::4861119254/followers)  - X Week XXXXX +2.60% - X Month XXXXX +5.10% - X Months XXXXX +37% - X Year XXXXX +60% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::4861119254/influencer_rank)  ### Social Influence [#](/creator/twitter::4861119254/influence) --- **Social category influence** [finance](/list/finance) [stocks](/list/stocks) [travel destinations](/list/travel-destinations) [countries](/list/countries) [cryptocurrencies](/list/cryptocurrencies) **Social topic influence** [acquisition](/topic/acquisition), [$abvx](/topic/$abvx), [bloomberg](/topic/bloomberg), [ticker](/topic/ticker), [$gald](/topic/$gald), [$sdzny](/topic/$sdzny), [swiss](/topic/swiss), [$rxdx](/topic/$rxdx), [dec](/topic/dec), [$bcax](/topic/$bcax) **Top assets mentioned** [Prometheus Biosciences, Inc. Common Stock (RXDX)](/topic/$rxdx) [Banco Bilbao Vizcaya Argentaria, S.A. (BBVA)](/topic/$bbva) [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Novartis AG (NVS)](/topic/novartis) [Johnson & Johnson (JNJ)](/topic/$jnj) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Amgen, Inc. (AMGN)](/topic/$amgn) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) [ROGin AI (ROG)](/topic/$rog) ### Top Social Posts [#](/creator/twitter::4861119254/posts) --- Top posts by engagements in the last XX hours "@seedy19tron It was even shorter with RXDX: X months between the Phase 2b readout in Dec XX and the Merck acquisition offer in April23. From $XX before Phase X to $XXX b/o"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948349594099732862) 2025-07-24 11:48:36 UTC 2224 followers, XXX engagements "@_financeken @seedy19tron Yes there is even a Bloomberg article mentioning a couple of them as part of the bidding process. And alsolater there was another acquisition by Roche (I own it) for Telavant which was part of Roivant (by then I had a position). So yes this space has b/o all over it"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948360764554707346) 2025-07-24 12:32:59 UTC 2225 followers, XX engagements "@PersimmonTI Yesintriguing and with volume. On the other hand $BCAX is also up (I was wondering if there was some analyst note out there on these X but could not find anything)"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1945919390123204957) 2025-07-17 18:51:50 UTC 2231 followers, XXX engagements "Of all my positions my eyes are focused on this name the mostI was literally back and forth on whether to trim or not checking my numbers etc. And average cost is in the low $30s. So I opted to trim and decided add back those shares if there is a little pullback. If there is no pullback I will let the rest ride (in my head there is an end scenario)"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948794041379729709) 2025-07-25 17:14:40 UTC 2231 followers, XXX engagements "Guggenheim Museum in Bilbao is a must-visit. Here an architectural legacy reimagined via AI (a model trained with 32mm images). Model even hallucinates and new landscapes emerge. Musical composition also AI-based. Way more than just these pics and video"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1941604853018464530) 2025-07-05 21:07:24 UTC 2224 followers, XXX engagements "@unusual_whales Not looking into what I have perhaps I would buy Swiss Re - in the US $SSREY (I should not have sold the Swiss ticker $SREN) or $BBVA"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1946808854978707596) 2025-07-20 05:46:15 UTC 2206 followers, 1088 engagements "@WallStSai Why would they do that after signing a multibillion deal with Zealand I would rather prefer that Rich acquires $ZEAL down the road"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948567122440757350) 2025-07-25 02:12:59 UTC 2231 followers, XXX engagements "Yesa lot of examples. There are others (the majority perhaps) that had a temporary bump absorbed the secondary and then continued their way. An example of a name I own with this condition: $MRUS . Secondary at $XX in Maytemporary dipand then at this very moment: trading at ATH. The ones really impacted are those with bad data"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948029134539817084) 2025-07-23 14:35:12 UTC 2217 followers, XXX engagements "@WallStSai That would be a positive for Swiss pharma names. In addition to Roche and Novartis: Sandoz $SDZ ( $SDZNY in the US) Lonza $LONN ( $LZAGY in the US) Galderma $GALD (only Swiss ticker) there are others. Not sure about the impact on US names but it could help"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1941198838754312491) 2025-07-04 18:14:03 UTC 2230 followers, 3360 engagements "@MaxTheComrade I agree. I am gradually accumulating that name"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948029269612868019) 2025-07-23 14:35:45 UTC 2211 followers, XXX engagements "@cp_option Prometheus data came in December 2022. Merck PR b/o announcement came in April 2023. Quite fast to be honest. All this is public data and can be obtained by anyone via simple search. Happy to help but I do expect people to do their own homework as well"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948238425125003531) 2025-07-24 04:26:51 UTC 2228 followers, XX engagements "To answer your question about $ABVX some context: I owned Prometheus ( $RXDX ). Back then it used to be my 2nd bio. Different MOA but same indications: UC and CD. It was taken out by Merck at $10.8b after the Phase 2b readout. That component is now named MK-7240 and is currently on Phase X study underway. $ABVX just released Phase X results (maintenance next year) so unless I am missing something both might hit the market around the same timeframe in 27/28. If RXDX was taken out at $10.8b and ABVX is current a little over $4bthen I would expect a similar valuation as hypothesis. I regret not"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948232271032397871) 2025-07-24 04:02:24 UTC 2228 followers, XXX engagements "@WallStSai Where I would hypothesize them to be active is in either their Neurology or Immunology divisions - there is a much bigger need. Or maybe a MASH asset for their CVRM division"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948572224673169651) 2025-07-25 02:33:15 UTC 2231 followers, XXX engagements "Added to $ABVX at $XXXX (20% more shares). Now avg. $XXXX. I will hold this position for a while"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1947932882669892028) 2025-07-23 08:12:44 UTC 2229 followers, 4895 engagements "Wilson - thanks a lot for sharing your knowledge and perspectives. With all my limitations my hypothesis also goes in that direction. The key question: is Petosentamab capable (as mono or with Keytruda) become SoC for HNSCC And if so how big the TAM is and what the potential is The company in its corporate presentation (see Investor Relations page) makes a good description at a high level of this component some results (there was a positive ASCO update a couple of months ago. Slide XX of the corp presentation gives you some numbers that you could use as reference. In addition to that: there"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948820927434641736) 2025-07-25 19:01:31 UTC 2229 followers, XXX engagements "@nataninvesting @Kross_Roads Yes and many more: Gilead $GILD Sandoz $SDZNY (disc: long this one via SDZN in the Swiss market) Amgen $AMGN $JNJ (not ATH but performing well) etc etc"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948444548755325124) 2025-07-24 18:05:55 UTC 2231 followers, XXX engagements "@PersimmonTI A secondary should be absorbed quickly when it happens. There are companies that kept going up after a secondary when the data was so compelling. I always remember Sierra Oncology: great data upthen secondaryupthen upthen buyout a couple months later. Many other cases"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948025335762632847) 2025-07-23 14:20:07 UTC 2212 followers, XXX engagements "And to $CTMX - I am still hoping to get it lower"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948745974286836023) 2025-07-25 14:03:40 UTC 2231 followers, 1119 engagements "@plainyogurt21 @Sanctuary_Bio @synapse_surfer Maybe not the right comparisonbut somehow the KITE / JUNO pair from years ago come to mind to me"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1949093293825892438) 2025-07-26 13:03:48 UTC 2231 followers, XXX engagements "Sure. I like the company and I believe that there is potential with the asset. The readout (like with any trial) has risks but that is ok. What made me uncomfortable is the level of bullishness that I am observingreaching unrealistic levels. There is even talks about competing bidding when the readout is not even there. I prefer to book profits and watch from the sidelines. I have other names to focus on that are working well. Best of lucks"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948774909636644968) 2025-07-25 15:58:39 UTC 2228 followers, XXX engagements "@A_May_MD @Biohazard3737 Interesting curve indeed. I might need to look at Galderma as they trade here in under $GALD"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1934714174766010595) 2025-06-16 20:46:19 UTC 2226 followers, XXX engagements "@plainyogurt21 @Sanctuary_Bio @synapse_surfer Roughly: What are currently Yescarta and Breyanzi were back then similar CAR-T targeting CD-19 programs by those bio. Both were acquired within months. First Kite then Juno"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1949098956786442307) 2025-07-26 13:26:18 UTC 2231 followers, XXX engagements "@paras_biotech Thanks for sharing. Very interesting. Not sure why they assume that Merck USA and Merck KGaA are the same company. Completely separate entities"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1949122644210557359) 2025-07-26 15:00:25 UTC 2231 followers, XXX engagements "And another case closer to this one: Prometheus itself $RXDX (perhaps the closest reference to $ABVX) - as I was holding this one it came to my memory about the stock action immediately after. When the secondary was announced price went up the next day. And the buyout came a few months later. So yes many cases when a secondary does not result in a dip"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948058863627903389) 2025-07-23 16:33:20 UTC 2214 followers, XXX engagements "@A_May_MD Something fun: When Prometheus was acquired (this company is being soma y memories) there was a bidding process. X Pharma companies were interested back then (just X years ago). Bloomberg source back then -"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948241750599844155) 2025-07-24 04:40:04 UTC 2231 followers, XXX engagements "@seedy19tron The Prometheus RXDX acquisition is also a very good reference"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948316593378787766) 2025-07-24 09:37:28 UTC 2224 followers, XXX engagements "Agreed. I had Prometheus (RXDX) when bought out by Merck. If anything that acquisition looks the closest as reference for this case with the caveat that this case is a Phase X. On the other hand CD is still in Phase 2b for readout late 26if a b/o occurs I would be surprised if $10b. Why didnt I see $ABVX earlier 😬"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1947867167212384347) 2025-07-23 03:51:36 UTC 2231 followers, 2452 engagements "@Sanctuary_Bio @synapse_surfer And on your last paragraph I also agree. Valuation considering only HNSCC is still constructive as can be seen as there is clearly demand at these levels. The rest unproven. Synapse_surfer hope this is all helpful"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948823114273440161) 2025-07-25 19:10:12 UTC 2230 followers, XXX engagements "@MaxTheComrade Yes have a very small position. In the obesity sector I am overweight $MTSR and indirectly with Roche ( via $ROG in the Swiss market) but this one is more defensive in nature and I had it before Carmot"  [@JoseRestonVA](/creator/x/JoseRestonVA) on [X](/post/tweet/1948031307864482145) 2025-07-23 14:43:51 UTC 2219 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@JoseRestonVA Jose Hurtado
Jose Hurtado posts on X about acquisition, $abvx, bloomberg, ticker the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +152%
- X Month XXXXXX -XX%
- X Months XXXXXXX +22%
- X Year XXXXXXX +202%
Mentions: XX #
- X Month XX -XX%
- X Months XXX +39%
- X Year XXX +168%
Followers: XXXXX #
- X Week XXXXX +2.60%
- X Month XXXXX +5.10%
- X Months XXXXX +37%
- X Year XXXXX +60%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence finance stocks travel destinations countries cryptocurrencies
Social topic influence acquisition, $abvx, bloomberg, ticker, $gald, $sdzny, swiss, $rxdx, dec, $bcax
Top assets mentioned Prometheus Biosciences, Inc. Common Stock (RXDX) Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) Merus N.V. Common Shares (MRUS) Novartis AG (NVS) Johnson & Johnson (JNJ) Gilead Sciences, Inc. (GILD) Amgen, Inc. (AMGN) Metsera, Inc. Common Stock (MTSR) ROGin AI (ROG)
Top Social Posts #
Top posts by engagements in the last XX hours
"@seedy19tron It was even shorter with RXDX: X months between the Phase 2b readout in Dec XX and the Merck acquisition offer in April23. From $XX before Phase X to $XXX b/o"
@JoseRestonVA on X 2025-07-24 11:48:36 UTC 2224 followers, XXX engagements
"@_financeken @seedy19tron Yes there is even a Bloomberg article mentioning a couple of them as part of the bidding process. And alsolater there was another acquisition by Roche (I own it) for Telavant which was part of Roivant (by then I had a position). So yes this space has b/o all over it" @JoseRestonVA on X 2025-07-24 12:32:59 UTC 2225 followers, XX engagements
"@PersimmonTI Yesintriguing and with volume. On the other hand $BCAX is also up (I was wondering if there was some analyst note out there on these X but could not find anything)" @JoseRestonVA on X 2025-07-17 18:51:50 UTC 2231 followers, XXX engagements
"Of all my positions my eyes are focused on this name the mostI was literally back and forth on whether to trim or not checking my numbers etc. And average cost is in the low $30s. So I opted to trim and decided add back those shares if there is a little pullback. If there is no pullback I will let the rest ride (in my head there is an end scenario)" @JoseRestonVA on X 2025-07-25 17:14:40 UTC 2231 followers, XXX engagements
"Guggenheim Museum in Bilbao is a must-visit. Here an architectural legacy reimagined via AI (a model trained with 32mm images). Model even hallucinates and new landscapes emerge. Musical composition also AI-based. Way more than just these pics and video" @JoseRestonVA on X 2025-07-05 21:07:24 UTC 2224 followers, XXX engagements
"@unusual_whales Not looking into what I have perhaps I would buy Swiss Re - in the US $SSREY (I should not have sold the Swiss ticker $SREN) or $BBVA" @JoseRestonVA on X 2025-07-20 05:46:15 UTC 2206 followers, 1088 engagements
"@WallStSai Why would they do that after signing a multibillion deal with Zealand I would rather prefer that Rich acquires $ZEAL down the road" @JoseRestonVA on X 2025-07-25 02:12:59 UTC 2231 followers, XXX engagements
"Yesa lot of examples. There are others (the majority perhaps) that had a temporary bump absorbed the secondary and then continued their way. An example of a name I own with this condition: $MRUS . Secondary at $XX in Maytemporary dipand then at this very moment: trading at ATH. The ones really impacted are those with bad data" @JoseRestonVA on X 2025-07-23 14:35:12 UTC 2217 followers, XXX engagements
"@WallStSai That would be a positive for Swiss pharma names. In addition to Roche and Novartis: Sandoz $SDZ ( $SDZNY in the US) Lonza $LONN ( $LZAGY in the US) Galderma $GALD (only Swiss ticker) there are others. Not sure about the impact on US names but it could help" @JoseRestonVA on X 2025-07-04 18:14:03 UTC 2230 followers, 3360 engagements
"@MaxTheComrade I agree. I am gradually accumulating that name" @JoseRestonVA on X 2025-07-23 14:35:45 UTC 2211 followers, XXX engagements
"@cp_option Prometheus data came in December 2022. Merck PR b/o announcement came in April 2023. Quite fast to be honest. All this is public data and can be obtained by anyone via simple search. Happy to help but I do expect people to do their own homework as well" @JoseRestonVA on X 2025-07-24 04:26:51 UTC 2228 followers, XX engagements
"To answer your question about $ABVX some context: I owned Prometheus ( $RXDX ). Back then it used to be my 2nd bio. Different MOA but same indications: UC and CD. It was taken out by Merck at $10.8b after the Phase 2b readout. That component is now named MK-7240 and is currently on Phase X study underway. $ABVX just released Phase X results (maintenance next year) so unless I am missing something both might hit the market around the same timeframe in 27/28. If RXDX was taken out at $10.8b and ABVX is current a little over $4bthen I would expect a similar valuation as hypothesis. I regret not" @JoseRestonVA on X 2025-07-24 04:02:24 UTC 2228 followers, XXX engagements
"@WallStSai Where I would hypothesize them to be active is in either their Neurology or Immunology divisions - there is a much bigger need. Or maybe a MASH asset for their CVRM division" @JoseRestonVA on X 2025-07-25 02:33:15 UTC 2231 followers, XXX engagements
"Added to $ABVX at $XXXX (20% more shares). Now avg. $XXXX. I will hold this position for a while" @JoseRestonVA on X 2025-07-23 08:12:44 UTC 2229 followers, 4895 engagements
"Wilson - thanks a lot for sharing your knowledge and perspectives. With all my limitations my hypothesis also goes in that direction. The key question: is Petosentamab capable (as mono or with Keytruda) become SoC for HNSCC And if so how big the TAM is and what the potential is The company in its corporate presentation (see Investor Relations page) makes a good description at a high level of this component some results (there was a positive ASCO update a couple of months ago. Slide XX of the corp presentation gives you some numbers that you could use as reference. In addition to that: there" @JoseRestonVA on X 2025-07-25 19:01:31 UTC 2229 followers, XXX engagements
"@nataninvesting @Kross_Roads Yes and many more: Gilead $GILD Sandoz $SDZNY (disc: long this one via SDZN in the Swiss market) Amgen $AMGN $JNJ (not ATH but performing well) etc etc" @JoseRestonVA on X 2025-07-24 18:05:55 UTC 2231 followers, XXX engagements
"@PersimmonTI A secondary should be absorbed quickly when it happens. There are companies that kept going up after a secondary when the data was so compelling. I always remember Sierra Oncology: great data upthen secondaryupthen upthen buyout a couple months later. Many other cases" @JoseRestonVA on X 2025-07-23 14:20:07 UTC 2212 followers, XXX engagements
"And to $CTMX - I am still hoping to get it lower" @JoseRestonVA on X 2025-07-25 14:03:40 UTC 2231 followers, 1119 engagements
"@plainyogurt21 @Sanctuary_Bio @synapse_surfer Maybe not the right comparisonbut somehow the KITE / JUNO pair from years ago come to mind to me" @JoseRestonVA on X 2025-07-26 13:03:48 UTC 2231 followers, XXX engagements
"Sure. I like the company and I believe that there is potential with the asset. The readout (like with any trial) has risks but that is ok. What made me uncomfortable is the level of bullishness that I am observingreaching unrealistic levels. There is even talks about competing bidding when the readout is not even there. I prefer to book profits and watch from the sidelines. I have other names to focus on that are working well. Best of lucks" @JoseRestonVA on X 2025-07-25 15:58:39 UTC 2228 followers, XXX engagements
"@A_May_MD @Biohazard3737 Interesting curve indeed. I might need to look at Galderma as they trade here in under $GALD" @JoseRestonVA on X 2025-06-16 20:46:19 UTC 2226 followers, XXX engagements
"@plainyogurt21 @Sanctuary_Bio @synapse_surfer Roughly: What are currently Yescarta and Breyanzi were back then similar CAR-T targeting CD-19 programs by those bio. Both were acquired within months. First Kite then Juno" @JoseRestonVA on X 2025-07-26 13:26:18 UTC 2231 followers, XXX engagements
"@paras_biotech Thanks for sharing. Very interesting. Not sure why they assume that Merck USA and Merck KGaA are the same company. Completely separate entities" @JoseRestonVA on X 2025-07-26 15:00:25 UTC 2231 followers, XXX engagements
"And another case closer to this one: Prometheus itself $RXDX (perhaps the closest reference to $ABVX) - as I was holding this one it came to my memory about the stock action immediately after. When the secondary was announced price went up the next day. And the buyout came a few months later. So yes many cases when a secondary does not result in a dip" @JoseRestonVA on X 2025-07-23 16:33:20 UTC 2214 followers, XXX engagements
"@A_May_MD Something fun: When Prometheus was acquired (this company is being soma y memories) there was a bidding process. X Pharma companies were interested back then (just X years ago). Bloomberg source back then -" @JoseRestonVA on X 2025-07-24 04:40:04 UTC 2231 followers, XXX engagements
"@seedy19tron The Prometheus RXDX acquisition is also a very good reference" @JoseRestonVA on X 2025-07-24 09:37:28 UTC 2224 followers, XXX engagements
"Agreed. I had Prometheus (RXDX) when bought out by Merck. If anything that acquisition looks the closest as reference for this case with the caveat that this case is a Phase X. On the other hand CD is still in Phase 2b for readout late 26if a b/o occurs I would be surprised if $10b. Why didnt I see $ABVX earlier 😬" @JoseRestonVA on X 2025-07-23 03:51:36 UTC 2231 followers, 2452 engagements
"@Sanctuary_Bio @synapse_surfer And on your last paragraph I also agree. Valuation considering only HNSCC is still constructive as can be seen as there is clearly demand at these levels. The rest unproven. Synapse_surfer hope this is all helpful" @JoseRestonVA on X 2025-07-25 19:10:12 UTC 2230 followers, XXX engagements
"@MaxTheComrade Yes have a very small position. In the obesity sector I am overweight $MTSR and indirectly with Roche ( via $ROG in the Swiss market) but this one is more defensive in nature and I had it before Carmot" @JoseRestonVA on X 2025-07-23 14:43:51 UTC 2219 followers, XXX engagements